Almanack Investment Partners’s Taysha Gene Therapies TSHA Stock Holding History

Almanack Investment Partners’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	+44,950	New	+$266K	0.04%	227

Other funds holding TSHA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

AWM

Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Almanack Investment Partners's TSHA Position: Q2 2026 in Review

Almanack Investment Partners opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 44,950 shares worth $306K. The stake represents 0.04% of the portfolio and ranks #227 among its holdings.

61 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Almanack Investment Partners held 44,950 shares of Taysha Gene Therapies worth $306K as of Q2 2026.
Taysha Gene Therapies was a new Almanack Investment Partners position in Q2 2026.
Taysha Gene Therapies made up 0.04% of Almanack Investment Partners's portfolio in Q2 2026, its #227 holding.
61 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.